Compound amino acid injection for treating hepatic encephalopathy

A compound amino acid and hepatic encephalopathy technology, which is applied in the field of compound amino acid injection for the treatment of hepatic encephalopathy, to achieve the effects of promoting metabolism, correcting abnormal amino acid profiles, and reducing blood ammonia concentration at a high speed

Active Publication Date: 2008-12-31
MITSUBISHI PHARMA GUANGZHOU
View PDF0 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, with the deepening of clinical application research, researchers have a better understanding of the cause of hepatic encephalopathy. In addition to the false neurotransmitter theory

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0090] Example 1

[0091] Dissolve the following components in distilled water for injection according to the following parts by weight, adjust the pH value of the amino acid solution to neutral, sterilize and filter the solution, put the solution into a bottle or plastic bag, fill it with nitrogen, seal it, and heat it in a conventional way. Bacteria to prepare the injection of this example.

[0092] L-Isoleucine 12.12

[0093] L-Leucine 12.45

[0094] L-valine 11.73

[0095] L-Lysine Acetate 5.20

[0096] L-methionine 0.58

[0097] L-phenylalanine 0.39

[0098] L-threonine 2.82

[0099] L-tryptophan 0.92

[0100] L-Alanine 11.07

[0101] L-Arginine 20.26

[0102] L-Aspartic acid 0.26

[0103] L-histidine 4.08

[0104] L-Proline 6.98

[0105] L-serine 3.42

[0106] L-tyrosine 0.52

[0107] Glycine 7.11

[0108] L-cysteine ​​0.32

[0109] Sodium bisulfite 0.32

Example Embodiment

[0110] Example 2

[0111] According to the method of Example 1, the following components and parts by weight injection were prepared.

[0112] L-Isoleucine 11.95

[0113] L-Leucine 14.50

[0114] L-valine 11.50

[0115] L-lysine hydrochloride 4.60

[0116] L-methionine 0.60

[0117] L-phenylalanine 0.00

[0118] L-threonine 2.80

[0119] L-tryptophan 0.85

[0120] L-Alanine 11.00

[0121] L-Arginine 18.50

[0122] L-Aspartic acid 0.10

[0123] L-histidine 3.95

[0124] L-Proline 7.50

[0125] L-serine 3.40

[0126] L-tyrosine 0.65

[0127] Glycine 7.00

[0128] L-cysteine ​​0.20

[0129] Sodium bisulfite 0.20

Example Embodiment

[0130] Example 3

[0131] According to the method of Example 1, the following components and parts by weight injection were prepared.

[0132] L-Isoleucine 13.89

[0133] L-Leucine 12.00

[0134] L-valine 13.00

[0135] L-Lysine Acetate 6.20

[0136] L-methionine 0.30

[0137] L-phenylalanine 0.40

[0138] L-threonine 2.90

[0139] L-tryptophan 0.95

[0140] L-Alanine 11.00

[0141] L-Arginine 18.50

[0142] L-Aspartic acid 0.30

[0143] L-histidine 4.95

[0144] L-Proline 6.50

[0145] L-serine 3.60

[0146] L-tyrosine 0.25

[0147] Glycine 7.00

[0148] L-cysteine ​​0.40

[0149] Sodium bisulfite 0.40

[0150] The following specific clinical experiments will further illustrate the beneficial effects of the injection of the present invention.

[0151] 1. Controlled clinical trials

[0152] (1) Research methods

[0153] 1. Research objects:

[0154] Patients with chronic liver insufficiency with hepatic encephalopathy (≤II grade or subclinical) and / or hyperammonemia (blood ammonia...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides a compound amino acid injection with high Fischer rate for curing hepatic encephalopathy, which can rapidly lower the blood ammonia density. The present invention increases the weight parts of three branched amino acid and arginine and reduces the weight parts of sulfur amino acid and ammonia amino acid. The injection provided by the present invention is more conducive to regulating the plasma amino acid spectrum to be normal, increases the density of arginine, stably lowers the level of blood ammonia of the patient and improves the immunity of the organism, thus achieving the aim of rapidly improving the symptom of hepatic encephalopathy and replenishing nutrition. Therefore, the injection of the present invention has higher curing effect in improving hepatic encephalopathy.

Description

technical field [0001] The invention relates to a compound amino acid, in particular to a compound amino acid injection for treating hepatic encephalopathy. Background technique [0002] Hepatic encephalopathy (hepatic encephalopathy HE) used to be called hepatic coma. It is a syndrome caused by severe liver disease, based on metabolic disorders and dysfunction of the central nervous system. Its main clinical manifestations are disturbance of consciousness, abnormal behavior and coma. Most hepatic encephalopathy is caused by various cirrhosis of the liver, and it can also be caused by portosystemic shunt surgery to improve portal hypertension. The pathogenesis has not been fully understood so far. There are many theories at present, including the theory of ammonia poisoning and the theory of amino acid metabolism imbalance, which are the most researched and most reliable. [0003] According to the theory of amino acid metabolism imbalance, various amino acid preparations fo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K33/04A61P1/16A61P25/00A61K31/198A61K31/401A61K31/405A61K31/4172
Inventor 古川正人
Owner MITSUBISHI PHARMA GUANGZHOU
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap